Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Previously Treated Acute Myeloid Leukemia
Conditions
Interventions
guadecitabine
Treatment Choice (TC)
Locations
95
United States
University of Southern California
Los Angeles, California, United States
The University of Chicago Medical Center
Chicago, Illinois, United States
Franciscan Research Center
Indianapolis, Indiana, United States
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States
University of New Mexico School of Medicine
Albuquerque, New Mexico, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Start Date
March 16, 2017
Primary Completion Date
January 20, 2020
Completion Date
June 1, 2020
Last Updated
August 28, 2024
NCT05564390
NCT07320235
NCT06782542
NCT05886049
NCT07295951
NCT06284486
Lead Sponsor
Astex Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions